Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3206 - Biomarkers for afatinib and dasatinib treatment in triple negative breast cancer


10 Oct 2016


Poster display


Alexandra Canonici


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


A. Canonici1, M.F..K. Ibrahim1, K. Fanning1, M. Cremona2, C. Morgan2, B. Hennessy2, F. Solca3, J. Crown4, N. O'Donovan1

Author affiliations

  • 1 National Institute For Cellular Biotechnology, Dublin City University, 9 - Dublin/IE
  • 2 Medical Oncology Lab., Dip. Molecular Medicine, Royal College of Surgeons in Ireland, 9 - Dublin/IE
  • 3 Pharmacology And Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna/AT
  • 4 Dept Of Medical Oncology, St Vincents University Hospital, 4 - Dublin/IE


Abstract 3206


Triple negative breast cancer (TNBC) lacks expression of hormone receptors and amplification of HER2. There are currently no approved targeted therapies. EGFR is frequently overexpressed in TNBC and may be a rationale target. The activity of afatinib, an irreversible pan-HER TKI, was assessed alone and in combination with inhibitors of other promising targets for TNBC.


Sensitivity to afatinib and other targeted therapies was assessed using proliferation assays. IC50 and CI values were determined using CalcuSyn. Statistical analyses were performed on StatView software. Proteomic profiling was performed by Reverse Phase Protein Array (RPPA).


As previously shown (Ibrahim et al, ASCO 2014), the IC50 values for afatinib in 14 TNBC cell lines ranged from 0.007-5.0 µM. 3 of the 7 basal-like cell lines were sensitive to afatinib (IC50 


Afatinib in combination with dasatinib may have activity in TNBC. Bcl2 may be a predictive biomarker to identify patients who are more likely to benefit from this combination. RPPA results suggest that efficient inhibition of both ERK and Akt signalling may contribute to the synergistic anti-proliferative effects of afatinib combined with dasatinib.

Clinical trial identification

Legal entity responsible for the study

Dublin City University


Boehringer Ingelheim


A. Canonici, N. O'Donovan: Received research funding from Boehringer Ingelheim. F. Solca: Eployee of Boehringer Ingelheim. J. Crown: Received research funding from Boehringer Ingelheim; and travel, accommodation and expenses from Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings